Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

532 ARTÍCULOS , VIENDO DEL 406 AL 420

The Interplay between Diabetes and Alzheimer's Disease-In the Hunt for Biomarkers

Kubis-Kubiak A, Dyba A, Piwowar A.

Int J Mol Sci. 2020 Apr 15;21(8):2744. doi: 10.3390/ijms21082744.

Fluorinated Molecules and Nanotechnology: Future 'Avengers' against the Alzheimer's Disease?

Dabur M, Loureiro JA, Pereira MC.

Int J Mol Sci. 2020 Apr 23;21(8):2989. doi: 10.3390/ijms21082989.

Insulin and leptin as potential cognitive enhancers in metabolic disorders and Alzheimer's disease

Mejido DCP, Peny JA, Vieira MNN, Ferreira ST, De Felice FG.

Neuropharmacology. 2020 Jul;171:108115. doi: 10.1016/j.neuropharm.2020.108115. Epub 2020 Apr 25.

Current and Future of Alzheimer's Therapy with the Best Approach

Singh H, Chawla V, Bala R, Dureja H.

CNS Neurol Disord Drug Targets. 2020;19(9):691-697. doi: 10.2174/1871527319666200430000538.

Utility of Animal Models to Understand Human Alzheimer's Disease, Using the Mastermind Research Approach to Avoid Unnecessary Further Sacrifices of Animals

Qin T, Prins S, Groeneveld GJ, Van Westen G, de Vries HE, Wong YC, Bischoff LJM, de Lange ECM.

Int J Mol Sci. 2020 Apr 30;21(9):3158. doi: 10.3390/ijms21093158.

Combination Drug Therapy for the Management of Alzheimer's Disease

Kabir MT, Uddin MS, Mamun AA, Jeandet P, Aleya L, Mansouri RA, Ashraf GM, Mathew B, Bin-Jumah MN, Abdel-Daim MM.

Int J Mol Sci. 2020 May 5;21(9):3272. doi: 10.3390/ijms21093272.

Clinical significance of fluid biomarkers in Alzheimer's Disease

Lewczuk P, Łukaszewicz-Zając M, Mroczko P, Kornhuber J.

Pharmacol Rep. 2020 Jun;72(3):528-542. doi: 10.1007/s43440-020-00107-0. Epub 2020 May 8.

Editorial: A Is for Amyloid

Selkoe DJ.

J Prev Alzheimers Dis. 2020;7(3):140-141. doi: 10.14283/jpad.2020.27.

Editorial: An Industry Perspective: Future of Anti-Amyloid Trials

Kramer LD.

J Prev Alzheimers Dis. 2020;7(3):142-143. doi: 10.14283/jpad.2020.26.

Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer's Disease

Khan S, Barve KH, Kumar MS.

Curr Neuropharmacol. 2020;18(11):1106-1125. doi: 10.2174/1570159X18666200528142429.

Exploring the Potential of Neuroproteomics in Alzheimer's Disease

Uddin MS, Kabir MT, Jakaria M, Sobarzo-Sánchez E, Barreto GE, Perveen A, Hafeez A, Bin-Jumah MN, Abdel-Daim MM, Ashraf GM.

Curr Top Med Chem. 2020;20(25):2263-2278. doi: 10.2174/1568026620666200603112030.

Biosensing: The best alternative for conventional methods in detection of Alzheimer's disease biomarkers

Mobed A, Hasanzadeh M.

Int J Biol Macromol. 2020 Oct 15;161:59-71. doi: 10.1016/j.ijbiomac.2020.05.257. Epub 2020 Jun 3.

Alzheimer's Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention Trials

Rafii MS.

CNS Drugs. 2020 Aug;34(8):785-794. doi: 10.1007/s40263-020-00740-6.

Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer's Disease Treated with Escalating Doses for up to 133 Weeks

Guthrie H, Honig LS, Lin H, Sink KM, Blondeau K, Quartino A, Dolton M, Carrasco-Triguero M, Lian Q, Bittner T, Clayton D, Smith J, Ostrowitzki S.

J Alzheimers Dis. 2020;76(3):967-979. doi: 10.3233/JAD-200134.

Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer's disease model

Wang S, Mustafa M, Yuede CM, Salazar SV, Kong P, Long H, Ward M, Siddiqui O, Paul R, Gilfillan S, Ibrahim A, Rhinn H, Tassi I, Rosenthal A, Schwabe T, Colonna M.

J Exp Med. 2020 Sep 7;217(9):e20200785. doi: 10.1084/jem.20200785.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias